Skip to main content
Top
Published in: Journal of Cancer Survivorship 3/2016

01-06-2016

Racial and ethnic disparities in cost-related medication non-adherence among cancer survivors

Authors: Minjee Lee, Ramzi G. Salloum

Published in: Journal of Cancer Survivorship | Issue 3/2016

Login to get access

Abstract

Purpose

Cancer survivors are delaying or avoiding necessary care due to costs, and medication non-adherence is an important aspect of deferred treatment. This study estimates the prevalence of cost-related medication non-adherence (CRN) by race and ethnicity and examines factors associated with CRN among cancer survivors.

Methods

Using the 2006–2013 National Health Interview Survey, we examine self-reported CRN among cancer survivors compared with cancer-free controls. Descriptive statistics and multiple logistic regression models were used to identify factors associated with CRN among cancer survivors.

Results

In a nationally representative sample of 472,542 adults, 10,998 participants reported a history of cancer and 461,544 did not. Among 10,998 cancer survivors, 1397 (12.70 %) reported CRN. Among older cancer survivors, African-Americans were 2.64 times more likely (95 % confidence interval (CI), 1.73 to 4.01) and Hispanics 2.07 times more likely (95 % CI, 1.32 to 3.24) than whites to report CRN. Among younger cancer survivors, Hispanics were 1.61 times more likely (95 % CI, 1.23 to 2.10) than whites to report CRN.

Conclusions

Significant racial and ethnic disparities in CRN were evident among cancer survivors. Older African-American and Hispanic overall survivors were more likely to report CRN in the past year compared with non-Hispanic whites.

Implications for Cancer Survivors

Given increasing prescription drug expenditure, it is important to closely monitor CRN in high-risk subgroups. Racial and ethnic minority groups at high risk for CRN should be counseled on the importance of medication adherence and offered support services to promote medication adherence. Further studies are warranted to establish effective policies and interventions in vulnerable populations.
Literature
1.
go back to reference Schumock GT, Li EC, Suda KJ, Matusiak LM, Hunkler RJ, Vermeulen LC, et al. National trends in prescription drug expenditures and projections for 2014. Am J Health Syst Pharm. 2014;71(6):482–99. doi:10.2146/ajhp130767.CrossRefPubMed Schumock GT, Li EC, Suda KJ, Matusiak LM, Hunkler RJ, Vermeulen LC, et al. National trends in prescription drug expenditures and projections for 2014. Am J Health Syst Pharm. 2014;71(6):482–99. doi:10.​2146/​ajhp130767.CrossRefPubMed
4.
go back to reference Tamblyn R, Laprise R, Hanley JA, Abrahamowicz M, Scott S, Mayo N, et al. Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA. 2001;285(4):421–9.CrossRefPubMed Tamblyn R, Laprise R, Hanley JA, Abrahamowicz M, Scott S, Mayo N, et al. Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA. 2001;285(4):421–9.CrossRefPubMed
7.
go back to reference Davidoff AJ, Erten M, Shaffer T, Shoemaker JS, Zuckerman IH, Pandya N, et al. Out-of-pocket health care expenditure burden for Medicare beneficiaries with cancer. Cancer. 2013;119(6):1257–65. doi:10.1002/cncr.27848.CrossRefPubMed Davidoff AJ, Erten M, Shaffer T, Shoemaker JS, Zuckerman IH, Pandya N, et al. Out-of-pocket health care expenditure burden for Medicare beneficiaries with cancer. Cancer. 2013;119(6):1257–65. doi:10.​1002/​cncr.​27848.CrossRefPubMed
8.
go back to reference Gornick ME. A decade of research on disparities in Medicare utilization: lessons for the health and health care of vulnerable men. Am J Public Health. 2008;98(9 Suppl):S162–8.CrossRefPubMedPubMedCentral Gornick ME. A decade of research on disparities in Medicare utilization: lessons for the health and health care of vulnerable men. Am J Public Health. 2008;98(9 Suppl):S162–8.CrossRefPubMedPubMedCentral
9.
go back to reference King CJ, Chen J, Dagher RK, Holt CL, Thomas SB. Decomposing differences in Medical care access among cancer survivors by race and ethnicity. Am J Med Qual. 2014. doi:10.1177/1062860614537676. King CJ, Chen J, Dagher RK, Holt CL, Thomas SB. Decomposing differences in Medical care access among cancer survivors by race and ethnicity. Am J Med Qual. 2014. doi:10.​1177/​1062860614537676​.
10.
go back to reference Nekhlyudov L, Madden J, Graves AJ, Zhang F, Soumerai SB, Ross-Degnan D. Cost-related medication nonadherence and cost-saving strategies used by elderly Medicare cancer survivors. J Cancer Surviv Res Pract. 2011;5(4):395–404. doi:10.1007/s11764-011-0188-4.CrossRef Nekhlyudov L, Madden J, Graves AJ, Zhang F, Soumerai SB, Ross-Degnan D. Cost-related medication nonadherence and cost-saving strategies used by elderly Medicare cancer survivors. J Cancer Surviv Res Pract. 2011;5(4):395–404. doi:10.​1007/​s11764-011-0188-4.CrossRef
11.
go back to reference Shin DW, Park JH, Park JH, Park EC, Kim SY, Kim SG, et al. Antihypertensive medication adherence in cancer survivors and its affecting factors: results of a Korean population-based study. Support Care Cancer. 2010;19(2):211–20. doi:10.1007/s00520-009-0802-4.CrossRefPubMed Shin DW, Park JH, Park JH, Park EC, Kim SY, Kim SG, et al. Antihypertensive medication adherence in cancer survivors and its affecting factors: results of a Korean population-based study. Support Care Cancer. 2010;19(2):211–20. doi:10.​1007/​s00520-009-0802-4.CrossRefPubMed
12.
go back to reference Sabatino SA, Coates RJ, Uhler RJ, Alley LG, Pollack LA. Health insurance coverage and cost barriers to needed medical care among U.S. adult cancer survivors age < 65 years. Cancer. 2006;106(11):2466–75. doi:10.1002/cncr.21879.CrossRefPubMed Sabatino SA, Coates RJ, Uhler RJ, Alley LG, Pollack LA. Health insurance coverage and cost barriers to needed medical care among U.S. adult cancer survivors age < 65 years. Cancer. 2006;106(11):2466–75. doi:10.​1002/​cncr.​21879.CrossRefPubMed
13.
go back to reference National Center for Health Statistics (U.S.). Design and estimation for the National Health Interview Survey, 1995–2004. Vital and health statistics series 2, data evaluation and methods research, vol. 130. Hyattsville: U.S. Dept. of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics; 2000. National Center for Health Statistics (U.S.). Design and estimation for the National Health Interview Survey, 1995–2004. Vital and health statistics series 2, data evaluation and methods research, vol. 130. Hyattsville: U.S. Dept. of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics; 2000.
14.
go back to reference Adams PF, Kirzinger WK, Martinez ME. Summary health statistics for the U.S. population: national health interview survey, 2011. Vital and health statistics series 10, data from the National Health Survey. 2012(255):1–110. Adams PF, Kirzinger WK, Martinez ME. Summary health statistics for the U.S. population: national health interview survey, 2011. Vital and health statistics series 10, data from the National Health Survey. 2012(255):1–110.
15.
go back to reference Parsons VL, Moriarity C, Jonas K, Moore TF, Davis KE, Tompkins L. Design and estimation for the national health interview survey, 2006–2015. Vital and health statistics series 2, data evaluation and methods research. 2014(165):1–53. Parsons VL, Moriarity C, Jonas K, Moore TF, Davis KE, Tompkins L. Design and estimation for the national health interview survey, 2006–2015. Vital and health statistics series 2, data evaluation and methods research. 2014(165):1–53.
16.
go back to reference Andersen RM. Revisiting the behavioral model and access to medical care: does it matter? J Health Soc Behav. 1995;36(1):1–10.CrossRefPubMed Andersen RM. Revisiting the behavioral model and access to medical care: does it matter? J Health Soc Behav. 1995;36(1):1–10.CrossRefPubMed
22.
go back to reference Guidry JJ, Aday LA, Zhang D, Winn RJ. Cost considerations as potential barriers to cancer treatment. Cancer Pract. 1998;6(3):182–7.CrossRefPubMed Guidry JJ, Aday LA, Zhang D, Winn RJ. Cost considerations as potential barriers to cancer treatment. Cancer Pract. 1998;6(3):182–7.CrossRefPubMed
26.
27.
go back to reference Byers TE, Wolf HJ, Bauer KR, Bolick-Aldrich S, Chen VW, Finch JL, et al. The impact of socioeconomic status on survival after cancer in the United States: findings from the National Program of Cancer Registries Patterns of Care Study. Cancer. 2008;113(3):582–91. doi:10.1002/cncr.23567.CrossRefPubMed Byers TE, Wolf HJ, Bauer KR, Bolick-Aldrich S, Chen VW, Finch JL, et al. The impact of socioeconomic status on survival after cancer in the United States: findings from the National Program of Cancer Registries Patterns of Care Study. Cancer. 2008;113(3):582–91. doi:10.​1002/​cncr.​23567.CrossRefPubMed
28.
34.
go back to reference Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol. 1997;50(1):105–16.CrossRefPubMed Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol. 1997;50(1):105–16.CrossRefPubMed
36.
go back to reference Braithwaite D, Tammemagi CM, Moore DH, Ozanne EM, Hiatt RA, Belkora J, et al. Hypertension is an independent predictor of survival disparity between African-American and white breast cancer patients. Int J Cancer. 2009;124(5):1213–9. doi:10.1002/ijc.24054.CrossRefPubMed Braithwaite D, Tammemagi CM, Moore DH, Ozanne EM, Hiatt RA, Belkora J, et al. Hypertension is an independent predictor of survival disparity between African-American and white breast cancer patients. Int J Cancer. 2009;124(5):1213–9. doi:10.​1002/​ijc.​24054.CrossRefPubMed
Metadata
Title
Racial and ethnic disparities in cost-related medication non-adherence among cancer survivors
Authors
Minjee Lee
Ramzi G. Salloum
Publication date
01-06-2016
Publisher
Springer US
Published in
Journal of Cancer Survivorship / Issue 3/2016
Print ISSN: 1932-2259
Electronic ISSN: 1932-2267
DOI
https://doi.org/10.1007/s11764-015-0499-y

Other articles of this Issue 3/2016

Journal of Cancer Survivorship 3/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine